文献速递心血管乳腺USMR

早期乳腺癌女性系列超声心动图和心脏磁共振中心肌功能障碍的表型

Phenotypes of Myocardial Dysfunction on Serial Echocardiography and CMR in Women With Early-Stage Breast Cancer.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-03-19

该研究为EMBRACE-MRI研究的二次分析,前瞻性纳入136例早期HER2+乳腺癌女性,每3个月行超声心动图和心肌生物标志物检测,基线与随访行CMR定量T1、T2和ECV。结果显示CTRCD发生37/136(27%),GLS恶化53/126(42%),新发舒张功能障碍按传统分级为25/129(19.4%)、改良分级为19/132(14.4%);舒张功能障碍与后续CTRCD风险升高相关(OR 20.9,95%CI 3.4-129.5),且与放疗剂量和ECV显著相关。

要点

  • 治疗期间首个异常状态可为GLS恶化、舒张功能障碍、CTRCD或组合出现。
  • 以LARS<24%替代左房容积的改良分级可提高舒张功能障碍分类能力。
  • 舒张功能障碍与后续CTRCD风险升高相关(OR 20.9),并与ECV和放疗剂量相关。

核心结论

  • 接受乳腺癌治疗的患者可出现显著的GLS变化、舒张功能障碍或CMR定义的CTRCD,可单独、同时或序贯发生;舒张功能障碍的发生与ECV相关且后续CTRCD风险更高。

研究设计与样本

  • EMBRACE-MRI研究(NCT02306538)的二次分析,前瞻性招募早期HER2+乳腺癌女性136例,年龄51.1±9.2岁,行系列超声心动图测量收缩和舒张功能及LARS,CMR定量心肌T1、T2和ECV,CTRCD由CMR衍生的左心室射血分数定义。

关键影像表现/征象

  • 治疗期间首个异常状态可为GLS恶化、舒张功能障碍、CTRCD或组合出现。
  • 首次转为舒张功能障碍者后续发生CTRCD的比例为5/8(63%),首次转为GLS恶化者为7/39(18%)。

诊断标准与关键数值

  • GLS相对降低>15%定义为「GLS恶化」。
  • 舒张功能障碍按美国超声心动图学会指南「传统」分级,并以LARS<24%替代左房容积「改良」重新分级。
  • CTRCD采用CMR衍生的左心室射血分数定义。

临床应用与阅片要点

  • 使用LARS可提高舒张功能障碍的分类能力。
  • 舒张功能障碍与后续CTRCD风险升高相关(OR 20.9,95%CI 3.4-129.5),GLS恶化与后续CTRCD相关(OR 4.9,95%CI 2.6-9.4)。
  • 舒张功能障碍与放疗剂量和ECV显著相关,但与血液生物标志物无关。

局限性

  • 本文为EMBRACE-MRI研究的二次分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Understanding phenotypic variations in left ventricular (LV) dysfunction during cancer therapy may allow for tailored surveillance and prevention.

OBJECTIVES: This study sought to determine LV dysfunction phenotypes during cancer therapy and their interrelated-ness and association with cancer therapy-related cardiac dysfunction (CTRCD), myocardial tissue changes, and blood biomarkers.

METHODS: This is a secondary analysis of the EMBRACE-MRI (Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI) study in which women with early-stage HER2+ breast cancer were recruited prospectively. High-sensitivity troponin I, B-type natriuretic peptide, and echocardiography were obtained pre-anthracycline and every 3 months with measurement of systolic and diastolic function and left atrial reservoir strain (LARS). Cardiac magnetic resonance (CMR) was performed at baseline and follow-ups with quantification of myocardial T1, T2, and extracellular volume (ECV). Diastolic dysfunction (DD) was graded using American Society of Echocardiography guidelines ("conventional") and regraded by replacing left atrial volume with LARS <24% ("modified"). Relative reduction in global longitudinal strain (GLS) >15% was considered "worsening GLS," and CTRCD was defined using CMR-derived left ventricular ejection fraction.

RESULTS: Among 136 women (age 51.1 ± 9.2 years), CTRCD developed in 37 of 136 (27%) and worsening GLS in 53 of 126 (42%) with analyzable studies. Incident DD occurred in 25 (19.4%) of 129 and 19 (14.4%) of 132 patients by conventional and modified grading, respectively. Using LARS improved the ability to classify DD. Transition state analysis demonstrated that the first abnormal state during cancer therapy could be worsening GLS, DD, CTRCD, or a combination. A greater proportion of patients who first transition to DD vs worsening GLS developed subsequent CTRCD (5 of 8 [63%]) vs 7 of 39 [18%]). Worsening DD was associated with higher odds of subsequent CTRCD (OR: 20.9, 95% CI: 3.4-129.5) vs worsening GLS (OR: 4.9, 95% CI: 2.6-9.4). DD was significantly associated with radiation dose and ECV but not with blood biomarkers.

CONCLUSIONS: Patients receiving breast cancer therapy can develop significant GLS change, DD, or CMR-defined CTRCD that can occur in isolation, concurrently, or sequentially. Development of DD is associated with ECV and higher risk for subsequent CTRCD. (Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI [EMBRACE-MRI]; NCT02306538).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Huang F, Rankin K, Sooriyakanthan M, et al. Phenotypes of Myocardial Dysfunction on Serial Echocardiography and CMR in Women With Early-Stage Breast Cancer. JACC Cardiovasc Imaging. 2025. PMID: 40117396. doi:10.1016/j.jcmg.2024.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。